PMC:3724992 / 19017-19664 JSONTXT

{"project":"2_test","denotations":[{"id":"23754640-16865273-63236744","span":{"begin":350,"end":352},"obj":"16865273"},{"id":"23754640-16141246-63236744","span":{"begin":350,"end":352},"obj":"16141246"},{"id":"23754640-15475460-63236744","span":{"begin":350,"end":352},"obj":"15475460"},{"id":"23754640-15974981-63236745","span":{"begin":639,"end":641},"obj":"15974981"},{"id":"23754640-15470029-63236746","span":{"begin":643,"end":645},"obj":"15470029"}],"text":"Over the past few years, the analysis of spontaneous immune responses to autologous tumors in cancer patients has allowed the identification of several kinds of tumor-associated antigens that can be the targets for tumor specific immune responses based on the recognition of tumor antigen by CTLs in an MHC-class I/peptide complex-restricted manner [29–31]. Therefore, cancer-specific immunotherapy has become an attractive fourth-therapeutic approach against carcinomas. Among them, one of the most relevant for the development of tumor immunotherapy is peptide-based, cancer-specific immunotherapy using the group of the tumor antigens [32, 33]."}